Liste des Groupes | Revenir à fb medecine |
Paul Aubrin a formulé la demande :Mettez-vous d'accord dans vos bovards avant de vous ridiculiser encore une fois.Le 16/06/2025 à 00:09, Every.body a écrit :>>C'est pourtant l'usage pour tous les vaccins: il faut un certain délaiSans doute, mais comme celui-là est censé tuer le patient, ils veulent compter les vaccinés dès l'injection. Pas de panique, il y a des survivants ?
pour que l'immunité soit acquise.
Pour évaluer le rapport bénéfice/risque complet, il faut comparer un échantillon représentatif qui a reçu le traitement à que échantillon représentation qui ne l'a pas reçu.
https://pubmed.ncbi.nlm.nih.gov/?term=covid19+vaccine+placebo&page=1
>
prenons la première
>
Results: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with PLACEBO. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to PLACEBO; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in PLACEBO recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and PLACEBO groups.
>
>
hop, pas besoin de dire merci
Les messages affichés proviennent d'usenet.